We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Oral Rehydration Therapy in Burn Patients (ORT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02124265
Recruitment Status : Terminated (Intervention appeared to be associated with increased nausea in some patients.)
First Posted : April 28, 2014
Results First Posted : February 18, 2019
Last Update Posted : February 18, 2019
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:

In patients with moderate to severe thermal injuries (> 20% TBSA) adequate fluid resuscitation is the main priority to achieve successful outcomes. Soon after burn injury substantial amounts of fluid accumulate rapidly in the wound while more is lost in the third space. Without intervention this process leads to hypotension and shock. The Parkland formula was devised to calculate how much intravenous (IV) fluid, i.e. crystalloids, is needed for adequate resuscitation during the first 24 hours post-burn. However, IV resuscitation can lead to overexpansion of (third space) volume, leading to severe complications such as compartment syndrome or pulmonary edema.

In major population centers, catastrophic events causing mass casualties will disrupt many hospital and emergency services, potentially delaying acute IV fluid resuscitation. Burn patient case reports have shown that oral rehydration therapy (ORT) used to supplement or in place of IV therapy is efficacious. ORT could be easily applied in mass burn casualties.

ORT is generally known in the third world for treating life-threatening dehydration due to diarrhea. The glucose-sodium co transport mechanism enables the affected human intestine to absorb a sufficient amount of water and electrolytes to replace large fluid losses due to severe diarrhea, even under adverse field conditions. No electrolyte disturbances have been recorded in such cases. Studies on enteral resuscitation in animal burn models showed high rates of small intestinal absorption which should be adequate for resuscitation following major burn injury.

The optimal composition of oral rehydration solution for resuscitation in burn wounds has not been determined. In cholera patients, Ceralyte® has proven superior to the World Health Organization Oral Rehydration Solution, increasing fluid absorption of the intestine. The Ceralyte® 90 solution, with 90mEq/L sodium and a low osmolarity of <275mOsm, may also contribute to optimal intestinal fluid uptake without causing electrolyte disturbances in thermal injury. ORT use might reduce the occurrence of compartment syndrome and pulmonary edema since fluid is regulated by the intestine according to physiologic requirements. The investigators propose to conduct a prospective study using Ceralyte® 90 to show that oral resuscitation therapy (ORT) in burns can reduce the total amount of IV fluid needed for adequate resuscitation and to test the efficacy and safety of ORT in the resuscitation of burn patients.

Condition or disease Intervention/treatment Phase
Burn Any Degree Involving 20-29 Percent of Body Surface Burn Any Degree Involving 30-39 Percent of Body Surface Burn Any Degree Involving 40-49 Percent of Body Surface Burn Any Degree Involving 50-59 Percent of Body Surface Burn Any Degree Involving 60-65 Percent of Body Surface Fluid Resuscitation Drug: CeraLyte 90 Phase 1

Detailed Description:

Primary objectives

  • To show that ORT in burns (using Ceralyte® 90) can reduce the total amount of intravenous fluid needed for adequate resuscitation.
  • To test the efficacy and safety of ORT in resuscitation of burn patients Secondary objectives.
  • To encourage further research on the use of ORT in large thermal injuries and mass casualty situations.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Oral Rehydration Therapy in Burn Patients Phase 1
Study Start Date : May 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Burns

Arm Intervention/treatment
Experimental: Ceralyte 90
Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
Drug: CeraLyte 90
  1. This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).
  2. Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.
  3. Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.

5. Patients will be monitored according to standard of care.

a. If gastric residuals are >300cc, ORT will be stopped and only IV fluid resuscitation will be used.

Primary Outcome Measures :
  1. Number of Participants With a 20% Decrease in Required IV Fluid. [ Time Frame: 24 hours post-burn ]

    Number of participants whose IV fluids were reduced to less than or equal to 80% of the Parkland Goal IV resuscitation formula within the first 24 hours of initial burn injury.

    To test the efficacy and safety of Oral RehydrationTherapy in resuscitation of burn patients

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients aged 18-65 years
  • Partial- to full-thickness burn injuries involving 20-65% of total body surface area (TBSA)

Exclusion Criteria:

  • Presence of inhalation injury
  • Hypotension or shock
  • Concomitant serious traumatic injury (i.e. head/ spine trauma)
  • Gastric Bypass Surgery
  • Small Bowel Obstruction
  • Delay in resuscitation >2 hrs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02124265

Layout table for location information
United States, Maryland
Johns Hopkins Bayview Burn Center
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Johns Hopkins University
Layout table for investigator information
Principal Investigator: Stephen M Milner, MBBS Johns Hopkins University
Additional Information:
Layout table for additonal information
Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT02124265    
Other Study ID Numbers: 00038778
First Posted: April 28, 2014    Key Record Dates
Results First Posted: February 18, 2019
Last Update Posted: February 18, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Only 3 patients were enrolled. No statistical analyses were performed.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Johns Hopkins University:
Oral Rehydration Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries